AI-Powered blood test could spot silent killer in septic patients
NCT ID NCT07630415
First seen Jun 13, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This study tests a new blood test that uses artificial intelligence to detect a life-threatening condition called disseminated intravascular coagulation (DIC) in patients with septic shock. DIC causes abnormal blood clotting and bleeding, and is often diagnosed too late. The test measures a marker called neutrophil fluorescence, which may signal the condition earlier. Researchers will enroll 492 adults in intensive care to see if the test works reliably in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University Hospitals of Strasbourg, Intensive Care Medicine Department - New Civil Hospital
Strasbourg, 67098, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
neutrophil fluorescence test on SthemA 801 analyzer with AI model
What this could lead to
If successful, this could provide a fast, reliable test to diagnose septic DIC early, potentially reducing deaths in intensive care.
What could go wrong
This is an early validation study, not yet proven in practice. The test may not be accurate enough or may not work in all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.